Recombinant Viral B18R Protein, CF

Catalog #: 8185-BR
5 Citations Datasheet / COA / SDS

Type I IFN Inhibitor

Catalog #	Availability	Size / Price	Qty
8185-BR-025

Get 50% off R&D Systems Recombinant Viral B18R Protein! Use Promo Code: B18R50. See offer details and Terms and Condition.

B18R Inhibits Type-I IFN-mediated anti-viral activity.

1 Image

Product Details

Citations (5)

Supplemental Products

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Viral B18R Protein, CF Summary

Product Specifications

Purity

>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

Activity

Measured by its ability to inhibit Type-I IFN-mediated anti-viral activity. Symons, J.A. et al. (1995) Cell 81:551. The ED₅₀ for this effect, as measured by inhibition of Recombinant Human IFN‑ alpha 2 (Catalog # 11105-1) , is 0.3-1.8 ng/mL.

Source

Human embryonic kidney cell, HEK293-derived viral B18R protein

MD	Human IgG₁ (Pro100-Lys300)	IEGR	Viral B18R (His20-Glu351) Accession # P25213
N-terminus			C-terminus

Accession #

P25213

N-terminal Sequence
Analysis

Met-Asp-Pro100

Structure / Form

Disulfide-linked homodimer

Predicted Molecular Mass

65 kDa (monomer)

SDS-PAGE

80-95 kDa, reducing conditions

Product Datasheets

8185-BR

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

8185-BR

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution	Reconstitute at 500 μg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied.

Scientific Data

Bioactivity

View Larger

The viral type I IFN receptor, B18R, inhibits the anti-viral activity of Recombinant Human IFN-alpha 2. The ED₅₀ for this effect is 0.3-1.8 ng/mL.

Reconstitution Calculator

Background: B18R

B18R (Soluble IFN alpha/beta receptor B18) is a 60-65 kDa protein encoded by the Vaccinia virus genome and by the genomes of other orthopoxviruses. Its function represents one of several mechanisms used by these viruses to evade the host immune response (1, 2). It is known as B18R in the Western Reserve (WR) strain of Vaccinia but as B19R in the Copenhagen strain (3). There is a structurally-unrelated, larger Vaccinia protein that is also known as B18R (or B16R) that contains multiple ankyrin-like repeats (4). The soluble IFN receptor B18R, however, contains three immunoglobulin-like domains and shows homology to human, mouse, and bovine type I IFN receptors (5). The Wyeth strain of Vaccinia virus encodes a truncated protein that lacks the C-terminal Ig-like domain, and B18R is functionally absent in the Lister strain (6, 7). B18R functions as a decoy receptor for type I IFNs (IFN alpha, beta, omega). It binds to type I IFNs from multiple species and prevents IFN signaling through its receptors (6-8). B18R binds to the surface of virus infected and uninfected cells where it retains its capacity to bind and neutralize IFN (6, 8). It shields those cells from the antiviral effects of type I IFNs, thereby enabling virus replication and pathogenicity (6-8). B18R also limits the effectiveness of IFN alpha produced following TLR activation (9), and it limits adaptive T cell responses (3). The B18R viral protein also acts to protect cells during mRNA transfection to produce induced pluripotent stem cells (iPSCs) from somatic cells (10). The addition of B18R results in increased cell viability of iPSCs in the presence of modified synthetic mRNAs such as OCT4, SOX2, KLF4, MYC, NANOG, and LIN28A. Using mRNAs in combination with B18R allows for integration-free reprogramming of somatic cells to iPSCs without the use of viral vectors or genomic modification.

References

Smith, G.L. et al. (2013) J. Gen. Virol. 94:2367.
Perdiguero, B. and M. Esteban (2009) J. Interferon Cytokine Res. 29:581.
Gomez, C.E. et al. (2012) J. Virol. 86:5026.
Goebel, S.J. et al. (1990) Virology 179:247.
Smith, G.L. and Y.S. Chan (1991) J. Gen. Virol. 72:511.
Alcami, A. et al. (2000) J. Virol. 74:11230.
Symons, J.A. et al. (1995) Cell 81:551.
Colamonici, O.R. et al. (1995) J. Biol. Chem. 270:15974.
Waibler, Z. et al. (2009) J. Virol. 83:1563.
Warren, L. et al. (2010) Cell Stem Cell. 7:618.

Long Name

Soluble Interferon alpha/beta Receptor B18

Entrez Gene IDs

3707577 (Viral)

Alternate Names

B18R

Related Research Areas

Citations for Recombinant Viral B18R Protein, CF

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

5 Citations: Showing 1 - 5
Filter your results:

Filter by:

Innate lymphoid cells are activated in HFRS, and their function can be modulated by hantavirus-induced type I interferons
Authors: García, M;Carrasco García, A;Weigel, W;Christ, W;Lira-Junior, R;Wirth, L;Tauriainen, J;Maleki, K;Vanoni, G;Vaheri, A;Mäkelä, S;Mustonen, J;Nordgren, J;Smed-Sörensen, A;Strandin, T;Mjösberg, J;Klingström, J;
PLoS pathogens
Species: Human
Sample Types: Whole Cells
Applications: Bioassay
MicroRNA-25/93 induction by Vpu as a mechanism for counteracting MARCH1-restriction on HIV-1 infectivity in macrophages
Authors: Lodge, R;Xu, Z;Eklund, M;Stürzel, C;Kirchhoff, F;Tremblay, MJ;Hobman, TC;Cohen, ÉA;
mBio
Species: Human
Sample Types: Whole Cells, Transfected Whole Cells
Applications: Bioassay
Interferon lambda 4 impairs hepatitis C viral antigen presentation and attenuates T cell responses
Authors: Q Chen, M Coto-Llere, A Suslov, RD Teixeira, I Fofana, S Nuciforo, M Hofmann, R Thimme, N Hensel, V Lohmann, CKY Ng, G Rosenberge, S Wieland, MH Heim
Nature Communications, 2021-08-12;12(1):4882.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay
MicroRNA Profiles in Monocyte-Derived Macrophages Generated by Interleukin-27 and Human Serum: Identification of a Novel HIV-Inhibiting and Autophagy-Inducing MicroRNA
Authors: T Imamichi, S Goswami, X Hu, S Laverdure, J Yang, J Qiu, Q Chen, BT Sherman, W Chang
International Journal of Molecular Sciences, 2021-01-28;22(3):.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization
Modulation of Extracellular ISG15 Signaling by Pathogens and Viral Effector Proteins
Authors: CD Swaim, LA Canadeo, KJ Monte, S Khanna, DJ Lenschow, JM Huibregtse
Cell Rep, 2020-06-16;31(11):107772.
Species: Human, Mouse
Sample Types: Whole Cells
Applications: Bioassay